Wellbutrin Xl 300
Important factors that could cause or contribute to such differences include risks relating to Teva's ability to rapidly integrate IVAX Corporation's operations and achieve expected synergies, Teva's ability to successfully develop and commercialize additional pharmaceutical products, the introduction of competing generic products, the impact of competition from brand-name companies that sell or license their own brand products under generic trade dress and at generic prices (so called "authorized generics") or seek to delay the introduction of generic product, the impact of consolidation of our distributors and customers, regulatory changes that may prevent Teva from exploiting exclusivity periods, potential liability for sales of generic products prior to a final resolution of outstanding litigation, including that relating to the generic versions of Allegra([R]), Neurontin([R]) and Zithromax([R]), the effects of competition on Copaxone([R]) sales, including as a result of the reintroduction of Tysabri([R]) into the market, the impact of pharmaceutical industry regulation and pending legislation that could affect the pharmaceutical industry, the difficulty of predicting U. "In addition, generic Wellbutrin wellbutrin xl 300 xl is the first of our Tier 3 products to be marketed under the 12-product Strategic Alliance Agreement signed with Teva in July 2001. IMPAX has filed a motion for summary judgment of noninfringement.
(NASDAQ: TEVA) announced today that it has commercially shipped Bupropion Hydrochloride Extended-Release Tablets, 300 mg, the generic version of Biovail Corporation's antidepressant Wellbutrin XL[R] Tablets, pursuant to an agreement with IMPAX Laboratories, Inc. Such statements are based on current expectations and involve a number of known and unknown risks and uncertainties that could cause IMPAX's future results, performance Wellbutrin xl 300 or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Sales of Wellbutrin XL tablets were wellbutrin xl 300 approximately $1 billion in the 12 months ended December 31, 2004 IMPAX Laboratories, Inc.
Food and Drug Administration (FDA) by Anchen Pharmaceuticals, Inc., seeking marketing approval for 150mg and 300mg generic formulations of Wellbutrin XL(R) (once-daily bupropion). The Company develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients, as well as animal health pharmaceutical products. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application (ANDA) for a generic version of Wellbutrin XL, 300 mg. Private Securities Litigation Reform Act of 1995: This release contains forward-looking wellbutrin xl 300 statements, which express the current beliefs and expectations of management.
Securities wellbutrin xl 300 and Exchange Commission. Food and Drug Administration ("FDA") and Canadian Therapeutic Products Directorate ("TPD") approvals, acceptance and demand for new pharmaceutical products, the impact of competitive products and pricing, new product development and launch, reliance on key strategic alliances, availability of raw materials and finished products, third parties, the regulatory environment, fluctuations in operating results and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission ("SEC") and the Ontario Securities Commission ("OSC"). In accordance with the relevant regulations, Biovail has a 45-day period in which to analyze the submission and determine if the intellectual property protecting Wellbutrin XL(R) has been infringed. Forward-looking statements include, but are not necessarily limited to, risks and uncertainties, including the difficulty of predicting U. Forward-looking statements are identified by words such as "believe", "anticipate", "expect", "intend", "plan", "will", "may" and other similar wellbutrin xl 300 expressions. Is a technology based specialty pharmaceutical company applying its formulation expertise and drug delivery technology to the development of controlled-release and specialty generics in addition to the development of branded products. Patent and Trademark Office. "We are confident in the strength of our intellectual property rights as they relate to Wellbutrin XL(R), and will Wellbutrin xl 300 defend these vigorously," said Dr.
domino | Wednesday 11th March 2009 06:22:54 AM
About Wellbutrin XL(R) Wellbutrin XL(R) is the first and only once-daily norepinephrine dopamine reuptake inhibitor (NDRI) for the treatment of depression in adults.
anja | Tuesday 24th March 2009 12:53:48 PM
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: Wellbutrin xl 300 to the extent any statements made in this news release contain information that is not historical, these statements are forward-looking in nature and express the beliefs and expectations of management.klaus | Monday 16th March 2009 06:41:38 PM
Wellbutrin XL(R) tablets incorporate wellbutrin xl 300 biovail's Smartcoat(TM) technology and have a two-layer coating designed to release drug slowly in the body.
domino | Wednesday 11th March 2009 09:20:29 PM
Biovail anticipates the issuance of this new patent by mid-2005.adam | Saturday 21st March 2009 08:57:29 PM
"Safe Harbor" Statement Under the Private Securities Litigation Reform Act of 1995 To the extent any statements made in this release contain information that is not historical, these statements are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.anja | Monday 2nd March 2009 09:49:44 AM
IMPAX markets Wellbutrin xl 300 its generic products through its Global Pharmaceuticals division and markets its branded products through the IMPAX Pharmaceuticals division.socha | Wednesday 11th March 2009 05:34:29 PM
Biovail Corporation undertakes no obligation to update or revise any forward-looking statement. NORTH WALES, Pa.
drumboy | Saturday 7th March 2009 09:28:12 PM
"Safe Harbor" statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this news release contain information that is not wellbutrin xl 300 historical, these statements are forward-looking in nature and express the beliefs and expectations of management.